American GLP

Medicare

Medicare Part D

Denise Ramirez, Coverage Editor · Updated August 2026

If you are on Medicare, you have probably been told Medicare does not cover weight-loss drugs. That was true for years and the law still says it. It is no longer the whole answer.

Two things are true at once right now. The statute still excludes drugs used for weight loss from Part D. And a separate CMS demonstration is paying for some of them at a $50 monthly copay through the end of 2027. Which one applies to you depends on why the drug is prescribed.

What the rules actually say

Federal law excludes drugs used for weight loss from Medicare Part D coverage. The statute's words are "agents when used for anorexia, weight loss, or weight gain" — the exclusion follows the use, not the drug.

42 U.S.C. §1396r-8(d)(2)(A), incorporated by §1395w-102(e)(2) · source · read August 2026

Because the exclusion follows the use, the same drug can be covered for a different approved indication. CMS states that type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH indications are eligible for Part D coverage.

Centers for Medicare & Medicaid Services, effective August 2026 · source · read August 2026

Since March 2024 Wegovy has an FDA approval to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight — an indication that is not weight loss.

US Food and Drug Administration, effective March 2024 · source · read August 2026

Since December 2024 Zepbound has an FDA approval for moderate to severe obstructive sleep apnea in adults with obesity.

US Food and Drug Administration, effective December 2024 · source · read August 2026

CMS is running a short-term demonstration, the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027, at a $50 monthly copay.

Centers for Medicare & Medicaid Services, effective August 2026 · source · read August 2026

The Bridge runs outside the normal Part D benefit. The $50 does not count toward your true out-of-pocket total, and low-income subsidies do not apply to it.

Centers for Medicare & Medicaid Services, effective August 2026 · source · read August 2026

Bridge eligibility is attested by your prescriber and needs a BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or 27 or more with pre-diabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

Centers for Medicare & Medicaid Services, effective August 2026 · source · read August 2026

You are not eligible for the Bridge if you have type 2 diabetes, obstructive sleep apnea or MASH — those route to ordinary Part D coverage instead — or if you already filled a GLP-1 through Part D in 2026.

Centers for Medicare & Medicaid Services, effective August 2026 · source · read August 2026

A 2025 proposed rule that would have added anti-obesity medication coverage to Part D was not finalized. CMS said so explicitly in April 2025, so any page describing that rule as law is wrong.

Centers for Medicare & Medicaid Services, effective April 2025 · source · read August 2026

What to do

  1. Find out which door you are at

    If you have type 2 diabetes, sleep apnea or MASH, you are asking Part D to cover an approved indication. If you have none of those, you are asking about the Bridge. They are different requests with different rules.

  2. Ask your prescriber to attest to the Bridge criteria

    The Bridge runs on a prescriber attestation of your BMI and qualifying condition. Nothing you do yourself starts it.

  3. If you are refused, use the Part D appeal clock

    You have 60 calendar days from the written coverage determination to file a redetermination, and 60 more from that decision to reach the independent review entity.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.

Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.

Where this comes from

  1. 42 U.S.C. §1396r-8(d)(2)(A), incorporated by §1395w-102(e)(2) — www.law.cornell.edu/uscode/text/42/1396r-8 (read August 2026)
  2. Centers for Medicare & Medicaid Services, effective August 2026 — www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1- (read August 2026)
  3. US Food and Drug Administration, effective March 2024 — www.fda.gov/news-events/press-announcements/fda-approves-first-treatment (read August 2026)
  4. US Food and Drug Administration, effective December 2024 — www.fda.gov/news-events/press-announcements/fda-approves-first-medicatio (read August 2026)
  5. Centers for Medicare & Medicaid Services, effective August 2026 — www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1- (read August 2026)
  6. Centers for Medicare & Medicaid Services, effective August 2026 — www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1- (read August 2026)
  7. Centers for Medicare & Medicaid Services, effective August 2026 — www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1- (read August 2026)
  8. Centers for Medicare & Medicaid Services, effective August 2026 — www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1- (read August 2026)
  9. Centers for Medicare & Medicaid Services, effective April 2025 — www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical (read August 2026)

Your state's Medicaid posture is in the coverage matrix, and the appeal routes are on the procedures page.